Cefiderocol and IV fosfomycin are exciting new options, and further clinical outcomes data will help define their roles.
Brandon Dionne, PharmD, BCPS-AQ ID, BCIDP, AAHIVP
Advertisement
Articles by Brandon Dionne, PharmD, BCPS-AQ ID, BCIDP, AAHIVP
Advertisement
Latest Updated Articles
New Antibiotics Treat Select Resistant InfectionsPublished: May 21st 2020 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Accelerated Approval of Cancer Drugs: Benefit or Burden?
2
FDA, HHS Move to Accelerate Biosimilar Approvals
3
Pharmacists Lead the Way in Evolving CAR T-Cell and Bispecific Antibody Therapy Management
4
COVID-19 mRNA Vaccines May Boost Immunotherapy Response in Cancer
5
